Ingenza and Ab Biotechnology Collaboration

Ingenza – a world-leading protein CRDMO – has today announced a strategic relationship with Ab Biotechnology – a MHRA‑licensed GMP facilities provider – to support the development and GMP manufacturing of innovative biotechnology products.
 

With the companies being located and operating in such close proximity, this relationship enables Ingenza and Ab Biotechnology to share complementary services and deliver a seamless and engaging experience for customers. This partnership not only enhances the GMP capabilities offered but it also supports cooperation and collaboration in an area well-renowned for its excellence in life science innovation.
 

The collaboration combines Ingenza’s cutting edge research and development expertise with Ab Biotechnology’s proven track record in GMP-compliant manufacturing, delivering an accelerated pathway from laboratory to scalable production. This partnership de-risks the transition from development to manufacturing by integrating strain, cell-line and process optimisation with established GMP expertise and infrastructure.
 

Nick Challoner, CEO at Ingenza commented, “We are delighted to partner with Ab Biotechnology as a pivotal part of our growth strategy. Ab Biotechnology are a fantastic partner with a long history of GMP manufacturing which will perfectly complement our AI/ML driven CRDMO services providing an enhanced service offering for our customers.”
 

Tam Cameron, CEO at Ab Biotechnology said, “We are excited to partner with Ingenza, this represents a significant milestone for Ab Biotechnology; by combining innovation with manufacturing excellence, we are creating a strong foundation for successful product development and commercialisation. Both in proximity and ethos the two companies could not be better aligned.”